One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
Use indexed eGFR and the qualifying genetic indication; this is not a daily or pediatric regimen.
What to reconcile: Confirm exact indication, indexed renal estimate and alternate-day schedule; use the newer primary label for full prescribing context.
Open this note and its source referencesConfirm exact indication, indexed renal estimate and alternate-day schedule; use the newer primary label for full prescribing context.
Dialysis evidence: Use is not recommended / excluded in the named dialysis population; not a dialysis dose
Confirm the qualifying amenable GLA variant. Avoid food and caffeine for 2 hours before and 2 hours after the dose; swallow the capsule whole.
The RX mirror shows 06/2024 while this primary label shows 03/2025. Only the named renal sections were reconciled, not the complete monographs.
| Renal setting | Source-specific action and limits |
|---|---|
| Mild/moderate renal impairment: eGFR >=30 mL/min/1.73 m2 | No renal dose adjustment. Labeled regimen: 123 mg orally every other day, not on consecutive days. |
| eGFR <30 mL/min/1.73 m2 or end-stage renal disease requiring dialysis | Not recommended; severe renal impairment has not been studied. |
| Renal setting | Source-specific action and limits |
|---|---|
| Mild/moderate renal impairment: eGFR >=30 mL/min/1.73 m2 | No renal dose adjustment. Labeled regimen: 123 mg orally every other day, not on consecutive days. |
| eGFR <30 mL/min/1.73 m2 or end-stage renal disease requiring dialysis | Not recommended; severe renal impairment has not been studied. |
Confirm the qualifying amenable GLA variant. Avoid food and caffeine for 2 hours before and 2 hours after the dose; swallow the capsule whole.
The RX mirror shows 06/2024 while this primary label shows 03/2025. Only the named renal sections were reconciled, not the complete monographs.
RDM68-migalastat-galafold-207a6d9781 · Source locator: Sections 1, 2.1, 2.2 and 8.6
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=migalastat-galafold&s1=RDM68-migalastat-galafold-official&h1=4d6fc7d0ca62db40bb6df76e202f8d4167245823e27da9cfde11ea5ae55f3005